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Abstract  
 
The cytotoxicity of PARP inhibitors olaparib, veliparib and CEP-8983 were investigated in 
two P-glycoprotein overexpressing drug-resistant cell models (IGROVCDDP and KB-8-5-
11). IGROVCDDP and KB-8-5-11 were both resistant to olaparib and resistance was 
reversible with the P-glycoprotein inhibitors elacridar, zosuquidar and valspodar. In contrast, 
the P-glycoprotein overexpressing models were not resistant to veliparib or CEP-8983. 
Olaparib and veliparib did not induce protein expression of P-glycoprotein in IGROVCDDP 
or KB-8-5-11 at doses which successfully inhibit PARP. Olaparib therefore appears to be a P-
glycoprotein substrate. Veliparib and CEP-8983 do not appear to be substrates. Veliparib and 
CEP-8983 may therefore be more useful in combined chemotherapy regimens with P-
glycoprotein substrates and may be active in platinum and taxane-resistant ovarian cancer. 
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Introduction 
Parp inhibitors are a new class of chemotherapy agents which target the FHOO¶V DNA damage 
repair pathways. PARP inhibitors are potentially very useful for treating BRCA1/2- 
dysfunctional cancers, as in these cancers the DNA repair machinery is already impaired. The 
results of proof of concept clinical trials of the PARP inhibitor olaparib in breast and ovarian 
cancer patients with germline BRCA1/2 mutations have been encouraging (1, 2). 
 
For any new chemotherapy agents it is important to establish if they are substrates of the 
classical ABC transporters, such as P-glycoprotein (P-gp). Agents that are not P-gp substrates 
may be more useful clinically, as if transporter driven drug resistance develops the cells are 
unlikely to be resistant to the wide range of chemotherapy drugs that are also P-gp substrates.  
P-gp mRNA has been detected in primary ovarian tumours (3), and its expression has been 
associated with poor overall survival (3). Between 16-25% of primary ovarian tumours are 
highly positive for P-gp by immunohistochemistry (IHC) (4-6). There is limited clinical data 
to support the induction of P-gp in the clinic, unlike in cancer cell lines treated with 
chemotherapy. Despite this, some studies have shown P-gp staining to increase in ovarian 
tumors after chemotherapy (6). P-gp has been shown to be an independent prognostic factor 
in some ovarian cancer studies (4) but not in others (5, 6). Similarly, between 44-66% (7, 8) 
of breast cancers stain positive for P-gp by IHC, some studies found it to be an independent 
prognostic factor (7) and others did not (8). Induction of P-gp in response to doxorubicin and 
epirubicin treatment was found to be predictive of survival in one breast cancer study (9). The 
role of P-gp in BRCA1 mutated clinical breast or ovarian cancer has not been studied in 
detail. However, a study which examined the gene expression profiles of BRCA1/2 tumours 
(n=34) vs sporadic ovarian cancer (n=27) in an Ashkenazi Jewish population did not find P-
gp to be significantly differentially expressed (10).  
 
There is currently limited data on the P-gp substrate status of PARP inhibitors. Olaparib has 
been shown to induce P-gp gene expression in an animal tumor model (11). Veliparib has 
been described as a weak P-gp substrate in a study using a P-gp transfected cell line (12). In 
contrast, the novel PARP inhibitor CEP-8983 has not been examined for its P-gp substrate 
status. There has also been no work to date examining PARP inhibitors using cell models of 
acquired drug resistance overexpressing P-gp. This study will examine the PARP inhibitors 
olaparib, veliparib and CEP-8983 in two cell models of acquired drug resistance where the 
major mechanism of drug resistance is overexpression of P-gp:- IGROVCDDP ovarian cells 
(13) and KB-8-5-11 cervical cells (14, 15). 
 
Materials and Methods 
 
2.1 Cell Culture and cytotoxicity assays 
 
IGROV-1 and IGROVCDDP ovarian cancer cells (16, 17) were obtained from Prof. Jan 
Schellens (Netherlands Cancer Institute) and grown as previously described (13). KB-3-1 and 
KB-8-5-11 cervical cancer cells (14, 15) were obtained from Prof. Michael Gottesman 
(National Cancer Institute) and grown in DMEM (Sigma), 1% Pen strep, 2% L-glutamine and 
1% Na Pyruvate with 10% FCS (Lonza). KB-8-5-11 cells were routinely grown in with 
colchicine; the drug was removed 3 days before the start of all experiments. All cell lines 
were maintained in a humidified atmosphere with 5% CO2 at 37°C. All cultures were tested 
routinely and were mycoplasma-free. All cell lines were STR fingerprinted to confirm 
identity. 
3 
 
 
PARP inhibitors olaparib and veliparib and zosuquidar were obtained from Selleck 
chemicals. CEP-8983 was obtained from Cephalon Inc. Elacridar was obtained from Santa 
Cruz Biotechnology. Valspodar was obtained from Sigma. To determine the cytotoxicity of 
the chemotherapy drugs, cells were plated into flat-bottomed, 96-well plates at a cell density 
of 2 x 104 cells/well and allowed to attach overnight. Twenty-four hours later wells were 
treated in triplicate with serial dilutions of drug in a final volume of 200 ȝ/The 
concentration ranges of chemotherapy drugs and P-gp inhibitors used for the cytotoxicity 
assays used on each cell line is given in Table S1. Drug-free controls were included in each 
assay. Plates were incubated for a further 5 days at 37°C in a humidified atmosphere with 5% 
CO2 and cell viability was determined using an acid phosphatase assay for IGROV-1, 
IGROVCDDP and an MTT assay for KB-3-1 and KB-8-5-11 (18). The MTT assay was used 
for KB-3-1 and KB-8-5-11 as these cell lines have a low-level of acid phosphatase yielding a 
low absorbance with confluent cells. Similarly, the acid phosphatase assay was used for 
IGROV-1 and IGROVCDDP as low absorbances were obtained on confluent cells with the 
MTT assay. 
 
2.2 Western blots 
 
The western blots were performed as previously described (13). Primary and secondary 
antibodies used are listed in Table S2.  
 
2.3 Taqman Low Density Arrays (TLDA) 
 
The TLDAs were performed as previously described (13). 
 
2.4 Statistical Analysis 
 
All experiments were performed at minimum in biological triplicate. Two-sample, two-tailed 
VWXGHQW¶VW-tests were used to determine significant differences using p d 0.05 as a cut off.   
 
Results 
IGROVCDDP and KB-8-5-11 are resistant to known P-gp substrates 
 
IGROVCDDP and KB-8-5-11 cells were resistant to known P-gp substrates doxorubicin and 
vincristine (Tables 1 and 2) (19). The resistance to these agents was reversed in both cell 
lines by treatment with P-gp inhibitors elacridar (20), zosuquidar and valspodar (21) (p  < 
0.05). The dose of 0.25µM elacridar has been previously shown to prevent P-gp transport 
activity in IGROVCDDP (13) and KB-8-5-11 cells (22) and has a minimal growth inhibitory 
effect. The doses of zosuquidar (1.5 PM) and valspodar (0.25 PM IGROV-1 and 
IGROVCDDP; 31.25 nM KB-3-1 and KB-8-5-11) were optimised to have a minimal growth 
inhibitory effect on the cell lines while reversing the known P-gp substrate doxorubicin. 
Zosuquidar used at 1 ± 3 PM has been previously shown in the literature to specifically 
reverse P-gp transport activity in a variety of cell models (23, 24). Similarly, valspodar has 
been shown to reverse P-gp activity in the dose range of 2 nM ± 4 PM. (25-27). 
 
Olaparib appears to be a P-glycoprotein substrate 
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IGROVCDDP cells were more resistant to olaparib than parental IGROV-1 cells (8.96-fold 
resistant, p = 6.88 x 10-9, Figure 1A, Table 1). Elacridar, zosuquidar and valspodar all 
partially reversed the olaparib resistance in IGROVCDDP (3.99-fold, 2.43-fold and 5.56 fold 
respectively, Figure 1A, Table 1). This reversal of resistance in IGROVCDDP in response to 
the inhibitors were all significant (p = 2.4 x 10-6, p = 7.81 x 10-6, p = 2.14 x 10-5 respectively). 
 
 
KB-8-5-11 cells were more resistant to olaparib than parental KB-3-1 cells (2.59-fold 
resistant, p = 1.38 x 104, Figure 1B). Elacridar, zosuquidar and valspodar all completely 
reversed the olaparib resistance in KB-8-5-11 (0.33-fold, 0.61-fold and 0.28 fold respectively, 
Figure 1B, Table 2). This reversal of resistance in KB-8-5-11 in response to the inhibitors 
were all significant (p = 4.73 x 10-5, p = 1.14 x 10-3, p = 9.08 x 10-9 respectively). 
 
 
Veliparib and CEP-8983 do not appear to be P-glycoprotein substrates 
 
IGROVCDDP and KB-8-5-11 were not resistant to veliparib (Tables 1 and 2). In general, 
treatment with the P-gp inhibitors had a mild sensitising effect on the cell lines. 
IGROVCDDP became resistant to veliparib at a very low-level (1.1 ± 1.23 fold) when treated 
in combination with zosuquidar or valspodar. While statistically significant, this low-level 
resistance is the product of a drop in IC50 of the parental IGROV-1 cell line, rather than a 
gain of resistance by the resistant cell line. 
 
IGROVCDDP was not resistant to CEP-8983 (Table 1). KB-8-5-11 were significantly 
resistant to CEP-8983 but at a very low-level (1.31 fold, p = 0.031, Table 2). This 1.31-fold 
resistance to CEP-8983 was not reversed in KB-8-5-11 by valspodar treatment. The fold 
resistance to CEP-8983 was reduced to 0.90 on treatment with zosuquidar. However, this was 
due to an increase in the IC50 of the parental KB-3-1 cells rather than a drop in IC50 of KB-8-
5-11.  The fold resistance to CEP-8983 was reduced to 1.06 on treatment with elacridar.  
 
Treatment with doses of olaparib and veliparib that inhibit PARP does not induce the 
expression of P-gp 
 
Olaparib and veliparib were chosen for further investigation. IGROV-1, IGROVCDDP, KB-
3-1 and KB-8-5-11 cells were treated with their IC50 doses of olaparib or veliparib for 72 
hours. IGROVCDDP and KB-8-5-11 cells both express significantly more P-gp than their 
parental cells. IGROVCDDP express 3-fold more P-gp than IGROV-1 (p = 0.005, Figures 
2A and B). P-gp was not detected in KB-3-1 cells by western blot so calculation of a fold 
increase in KB-8-5-11 was not possible. IC50 doses of olaparib and veliparib did not increase 
the expression of P-gp in any of the cell lines (Figures 2A and B). 
 
To confirm the inhibition of PARP at this dose and exposure time, a western blot of 
Poly(ADP-ribose) (PAR) was performed. Formation of PAR by PARP results in the releasing 
of PARP from damaged DNA (28). Therefore, PAR is a marker to indicate if PARP 
inhibitors have successfully inhibited PARP¶s activity. PAR has been used for this purpose in 
several clinical trials (29, 30). PAR expression was significantly decreased in IGROV-1 and 
KB-3-1 in response to both olaparib and veliparib. Reductions in the range of 14-29 fold were 
observed (p < 1.0x10-5, Figure 2C and D). Olaparib and veliparib decreased PAR expression 
in IGROVCDDP and KB-8-5-11 but these changes were only significant in response to 
veliparib in both cases. This indicates that the doses of parp inhibitors chosen for treatment 
were successful at inhibiting PARP. 
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Discussion 
 
Olaparib appears to be a P-gp substrate 
 
IGROVCDDP and KB-8-5-11 are suitable cell models for studying P-gp transport, as they 
both overexpress P-gp and no other ABC transporters such as MRP1-6 and BCRP (Table S3). 
P-gp has been previously shown to be functionally active by accumulation assays in both 
IGROVCDDP and KB-8-5-11 cells (13, 31).  
 
Olaparib was the only examined PARP inhibitor to which IGROVCDDP and KB-8-5-11 
were both resistant (8.96 and 2.59 fold respectively). This resistance was also significantly 
reversed by elacridar, zosuquidar and valspodar in both cell lines (Figure 1A and B). Very 
low-level resistance to CEP-8983 was observed in KB-8-5-11 (1.3-fold, p = 0.031). However, 
this resistance was not reversed by zosuquidar or valspodar treatment. Drug resistance when 
it occurs in the clinical treatment of cancer is typically in the range of 2-12 fold (32-38). 
Therefore, we are regarding the statistically significant 1.3 fold resistance to CEP-8983 in 
KB-8-5-11 as below the level of biological significance. Therefore, olaparib appears to be a 
P-gp substrate whereas veliparib and CEP-8983 appear not to be substrates (Tables 1 and 2).   
 
Resistance to olaparib has been previously shown to be associated with increased gene 
expression of P-gp in a mouse tumour model (11). In contrast, we do not see any induction of 
P-gp protein expression in response to a 72-hour olaparib treatment in any of the cell lines 
examined (Figure 2A and B). These same doses of drug were shown to decrease PAR, a 
marker of PARP inhibition (Figure 2C and D). However, it should be noted that it often takes 
a long-term exposure to a P-gp substrate, such as in drug-resistant cell line development to 
induce the expression of P-gp. We are currently developing parp-inhibitor resistant cell lines 
to address this issue. Veliparib was previously found to be a weak substrate for P-gp in 
transfected cells (12). Our results show that veliparib is not a substrate for P-gp in 
IGROVCDDP and KB-8-5-11 which are also consistent with these findings (Tables 1 and 2). 
 
The reversal of olaparib resistance by elacridar in IGROVCDDP was only partial compared 
to that seen in KB-8-5-11 (Figure 1). IGROVCDDP was 8.96-fold resistant to olaparib while 
KB-8-5-11 was only 2.59-fold resistant. Therefore, complete reversal may have been easier 
to achieve in KB-8-5-11. The partial reversal in IGROVCDDP may also be due to other non-
P-gp mechanisms of drug resistance that cause resistance to olaparib. IGROVCDDP cells are 
resistant to cisplatin. As platinums and olaparib both affect DNA damage and repair 
pathways there may be an overlap in the mechanisms of resistance between these agents. 
 
P-glycoprotein has a very broad substrate specificity and is believed to have multiple binding 
sites. Most of the classic P-gp substrates are natural products that cannot be unambiguously 
aligned with each other due to a lack of similar orientation points or chemical domains (39). 
Therefore, the presence or absence of a particular chemical domain cannot predict if a 
compound is a P-gp substrate. However, several factors relating to the structure of a 
FRPSRXQGFDQVXJJHVWLILW¶VD3-gp substrate. The chemical structures of olaparib, veliparib 
and CEP-8983 are given in Figure 3A-C. A molecular weight of >400 is typical of P-gp 
substrates (39), out of the drugs we investigated Olaparib is the only one exceeding 400 (MW 
434.46), Veliparib and CEP-8983 are smaller (MW 244.29 and MW 306.31 respectively). 
Compounds with a combined number of oxygen and nitrogen atoms t8 are often P-gp 
substrates, and d4 non-substrates (39). None of the parp inhibitors we have examined are 
easily defined by this rule. Olaparib has a combined number of 7 (N4O3) and Veliparib and 
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CEP-8983 both have a combined number of 5 (N4O1 and N2O3 respectively). However, 
Olaparib is higher towards the criteria of P-gp substrate and Veliparib and CEP-8983 are 
lower towards the criteria of non-substrate. This is consistent with our data (Tables 1 and 2). 
 
There are a variety of online in silico tools which can predict the P-gp substrate status of a 
compound based on its molecular structure. Using the tool developed by Wang et al, 
doxorubicin is predicted to be a P-gp substrate with a probability of 0.74 (40). Olaparib and 
Veliparib are both predicted to be substrates with probabilities of 0.87 and 0.77 respectively. 
CEP-8983 had a 0.55 probability of being a substrate. In contrast, another online tool which 
makes a binary substrate/non-substrate classification categorised olaparib as a substrate and 
veliparib as a non-substrate (41). This suggests that these tools are valuable for screening 
large numbers of compounds, but that there is still value in in vitro conformation of P-gp 
substrate status. 
 
Clinical implications 
P-gp in the intestine may become saturated with rapidly absorbed drugs due to the large 
concentration of drug present. Olaparib is rapidly absorbed in the intestine with peak-plasma 
levels occurring 1-3 hours after dosing (42, 43). This suggests that oODSDULE¶V3-gp substrate 
status is not having a significant impact on intestinal absorption. However, veliparib is 
absorbed faster than olaparib, peak-plasma levels occurring 0.5-1.5 hours after dosing (44). 
One factor in this faster absorption may be that veliparib is not a P-gp substrate. 
 
P-gp has a greater impact at the individual tissue level where the concentration of xenobiotic 
is lower compared to the intestine (45). The role of P-gp in clinical drug resistance is 
controversial, as outlined in the introduction with some studies finding it a prognostic marker 
(4, 7) and others not (5, 6, 8). As personalised biomarker panels are developed for ovarian 
and breast cancer treatment, it is potentially relevant to include P-gp, and to use this to guide 
the choice of parp inhibitor for an individual patient. 
 
The IGROVCDDP cisplatin-resistant ovarian cell line is an unusual model, as it is also cross-
resistant to paclitaxel which is mediated by P-gp (13). IGROVCDDP models the resistance 
phenotype of ovarian cancer patients who have failed standard frontline combination 
platinum/taxane chemotherapy. IGROVCDDP is not resistant to veliparib or CEP-8983. 
Therefore, these agents could be useful for the second-line treatment of platinum/taxane 
resistant ovarian cancer. 
 
The response rates of single-agent olaparib in relapsed platinum/taxane pre-treated ovarian 
cancer range from 12- 40% (1, 46-49). Response rates are higher in platinum-sensitive 
BRCA1/2-mutated ovarian cancer patients and range from 41-62% (1, 48, 49). Platinum 
sensitivity (relapse > 6 months after chemotherapy) is the most consistent predictive factor of 
response amongst salvage chemotherapy regimens in a pre-treated ovarian cancer (50-52). 
Therefore, platinum-sensitive patients who are also BRCA1/2 mutation carriers, have the best 
possible chance of responding to parp inhibitors. Conversely, pre-treated patients who are 
platinum-resistant (relapse d 6 months after chemotherapy) and BRCA1/2 wild-type patients 
have a much lower response rate to olaparib, 3.9% (48). 
 
Only one study has been published using veliparib for the treatment of relapsed 
platinum/taxane pre-treated ovarian cancer, which reported a response rate of 45% (n = 11). 
However, this study used veliparib in combination with cyclophosphamide and the small 
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cohort were all BRCA2 mutation carriers which could contribute to the higher response rate 
(30). It may be that there is a limited difference in response rate between olaparib and 
veliparib in the clinical treatment of relapsed ovarian cancer, which suggests that the impact 
of P-gp is limited in this setting. Unfortunately, P-gp was not examined as a marker in any of 
the olaparib and veliparib clinical studies. 
The maximal tolerated doses and the peak-plasma levels of olaparib are higher than veliparib 
in cancer patients (43, 44). Olaparib is also a more potent drug in vitro, the average IC50 in a 
panel of 17 BRCA1/2 wild-type ovarian cancer cell lines was 4.05 µM, compared to 
veliparib, average IC50 was 44.64µM (53). Olaparib may therefore be a more successful in 
the clinical treatment of cancer than veliparib by being a more potent drug that has a higher 
maximal tolerated dose in patients regardless of its P-gp substrate status. However, the 
combination of agents with differing mechanisms of cytotoxic action is routine in clinical 
cancer therapy. If a PARP inhibitor is to be combined with another class of agent which is a 
P-gp substrate, with other factors such as toxicity being equal, then veliparib or CEP-8983 
could be superior to olaparib. 
Conclusions 
 
Olaparib appears to be a P-glycoprotein substrate. In contrast, veliparib and CEP-8983 do not 
appear to be substrates. Veliparib and CEP-8983 may therefore be more useful in combined 
chemotherapy regimens with other P-gp substrates or as salvage chemotherapy after exposure 
to P-gp substrates. Veliparib and CEP-8983 may be useful in the treatment of platinum and 
taxane resistant ovarian cancer.  
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Figure Legends 
Figure 1 ± Cytotoxicity of olaparib. A) IGROV-1 and IGROVCDDP and B) KB-3-1 and 
KB-8-5-11. Open bars indicate parental cell lines, grey bars indicate resistant cell lines. 
Diagonally striped bars indicate treatment with 0.25µM elacridar. Vertically striped bars 
indicate treatment with 1.5 µM zosuquidar. Checked bars indicate treatment with 0.25 µM or 
31.25 nM valspodar (IGROVCDDP and KB-8-5-11 respectively). Graphs show means and 
standard deviation of a minimum of n = 3 biological repeats. * Indicates a significant 
difference of the resistant cell line from the parent cell line p d VWXGHQW¶VW-test.  # 
Indicates a significant difference on the addition of a P-gp inhibitor; p d VWXGHQW¶VW-test.  
 
Figure 2 ± P-gp and PAR protein expression in response to treatment with olaparib or 
veliparib. IGROV-1, IGROVCDDP, KB-3-1 and KB-8-5-11 cells were treated for 72 hours 
with an IC50 dose of olaparib or veliparib and compared to a drug-free control. Western blots 
are shown for A and B) P-gp and C and D) PAR. Representative images of n = 4 biological 
replicates are shown.  
 
Figure 3 ± Molecular structure of parp inhibitors used in the study. A) Olaparib, B) Veliparib 
and C) CEP-8983.   
 
Table 1 – Resistance profile of IGROVCDDP examining P-glycoprotein substrates 
Drug (Units) IGROV-1   
IC50 
 IGROVCDDP 
IC50 
 Resistant vs Sensitive IGROV-1   
+/- Inhibitor 
IGROVCDDP 
+/-  Inhibitor 
Mean ± SD n Mean ± SD n Fold P-value P-value P-value 
Known P-glycoprotein Substrates 
Doxorubicin (nM) 21.81 ± 3.73 4 86.04 ± 16.18 4 3.94 2.45E-04   
+ Elacridar 0.25 µM 12.80 ±0.77 3 12.97 ± 0.92 4 1.01 0.81 0.01 6.07E-04 
+ Zosuquidar 1.5 µM 12.52 ± 2.20 3 8.00 ± 1.27 4 0.64 0.02 0.01 7.24E-05 
+ Valspodar 0.25 µM  13.92 ±2.67 5 13.49 ± 1.18 4 0.97 0.80 7.71E-03 1.09E-04 
Vincristine (nM) 8.30 ±1.50 4 26.76 ± 4.24 4 3.22 1.76E-04   
+ Elacridar 0.25 µM 1.69 ± 0.14 4 0.26 ± 0.04 5 0.16 1.14E-07 1.21E-04 1.60E-05 
+ Zosuquidar 1.5 µM 1.35 ±0.12 4 0.27 ± 0.04 5 0.20 2.63E-06 9.03E-05 1.60E-05 
+ Valspodar 0.25 µM  1.48 ±0.20 4 0.55 ± 0.09 3 0.37 6.59E-04 1.04E-04 1.38E-04 
Parp Inhibitors 
Olaparib (µM) 1.25 ± 0.11 7 11.17 ± 1.98 8 8.96 6.88E-09   
+ Elacridar 0.25 µM 1.17 ± 0.11 4 4.65 ± 0.49 5 3.99 2.40E-06 0.27 2.30E-04 
+ Zosuquidar 1.5 µM 1.90 ± 0.31 5 4.63 ±  0.52 5 2.43 7.81E-06 1.47E-03 6.33E-05 
+ Valspodar 0.25 µM  1.45 ± 0.22 5 8.06 ± 1.66 4 5.56 2.14E-05 0.06 0.02 
Veliparib (µM) 54.23 ± 5.38 7 50.55 ±  8.33 9 0.93 0.328   
+ Elacridar 0.25 µM 45.88 ± 4.14 7 46.19 ± 7.83 10 1.01 0.926 6.92E-03 6.33E-02 
+ Zosuquidar 1.5 µM 44.34 ± 1.60 5 48.77 ± 3.42 8 1.10 0.021 2.78E-03 0.58 
+ Valspodar 0.25 µM  38.38 ± 3.41 4 47.13 ± 3.16 7 1.23 0.002 5.25E-04 0.32 
CEP-8983 (µM) 5.69 ± 0.75 8 5.35 ± 0.75 8 0.94 0.372   
+ Elacridar 0.25 µM 5.97 ± 1.07 9 5.48 ± 0.78 8 0.92 0.306 0.55 0.73 
+ Zosuquidar 1.5 µM 5.14 ± 0.81 6 4.09 ±  0.60 4 0.80 0.134 0.21 0.01 
+ Valspodar 0.25 µM  4.45 ±0.42 5 4.31 ± 0.61 5 0.97 0.692 0.01 0.03 
P-gp Inhibitors 
Elacridar (µM) 3.17 ± 0.12 4 1.62 ± 0.03 4 0.51 1.97E-06   
Zosuquidar (µM) 5.81 ± 0.64 4 5.72 ± 1.31 6 0.98 0.90   
Valspodar (µM)  4.15 ±  1.01 4 2.77 ±  0.71 6 0.67 0.03   
Table 2 – Resistance profile of KB-8-5-11 examining P-glycoprotein substrates 
Drug (Units) KB-3-1  IC50  KB-8-5-11 IC50  Resistant vs Sensitive KB-3-1  
+/- Inhibitor 
KB-8-5-11 
+/-  Inhibitor 
Mean ± SD n Mean ± SD n Fold P-value P-value P-value 
Known P-glycoprotein Substrates 
Doxorubicin (nM) 2.61 ±  0.19 3 142.72 ± 21.23 4 54.70 1.01E-04   
+ Elacridar 0.25 µM 2.53 ±  0.37 5 7.05 ± 7.05 4 2.79 2.13E-05 0.75 1.41E-05 
+ Zosuquidar 1.5 µM 1.69 ±  0.15 3 2.53 ± 2.53 4 1.50 0.03 2.77E-03 1.16E-05 
+ Valspodar 31.25 nM 3.03 ± 0.46 3 9.79 ± 9.79  3 3.23 9.84E-04 0.22 1.31E-04 
Vincristine (µM) 3.32E-08 ± 9.71E-09 4 5.61E-02 ± 8.91E-03 6 1.69E-06 0.04   
+ Elacridar 0.25 µM 2.40E-09 ± 8.86E-10 3 2.74E-09 ± 1.06E-09 3 1.14 0.69 3.06E-03 1.52E-05 
+ Zosuquidar 1.5 µM 6.65E-11 ± 1.81E-11 3 3.72E-10 ± 1.18E-10 3 5.60 0.01 2.19E-03 1.52E-05 
+ Valspodar 31.25 nM 5.29E-10 ± 2.31E-11 3 2.35E-05 ± 2.03E-06 4 4.45E-04 6.38E-06 2.34E-03 1.75E-05 
PARP Inhibitors 
Olaparib (µM) 17.98 ± 3.26 5 46.54 ± 6.82 6 2.59 1.38E-04   
+ Elacridar 0.25 µM 16.19 ± 1.80 5 5.32 ± 1.08 5 0.33 4.73E-05 0.56 6.33E-05 
+ Zosuquidar 1.5 µM 15.39 ± 2.49 8 9.39 ± 1.12 4 0.61 1.14E-03 0.25 1.05E-04 
+ Valspodar 31.25 nM 16.38 ± 0.92 5 4.59 ± 0.58 5 0.28 9.08E-09 0.55 6.78E-06 
Veliparib (µM) 52.97 ± 4.05 4 51.43 ± 1.03 4 0.97 0.490   
+ Elacridar 0.25 µM 53.06 ± 7.90 6 45.49 ± 4.23 5 0.86 0.088 0.98 0.03 
+ Zosuquidar 1.5 µM 54.84 ± 9.97 5 44.01 ± 4.91 4 0.80 0.089 0.83 0.03 
+ Valspodar 31.25 nM 46.31 ± 3.68 4 38.37 ± 5.75 6 0.83 0.042 0.05 5.46E-04 
CEP-8983 (µM) 73.86 ± 11.86 4 96.71 ± 11.23 4 1.31 0.031   
+ Elacridar 0.25 µM 30.66 ± 2.01 3 32.37 ± 1.09 4 1.06 0.246 3.69E-04 2.02E-04 
+ Zosuquidar 1.5 µM 110.02 ± 23.06 3 99.08 ± 10.73 4 0.90 0.944 0.02 0.77 
+ Valspodar 31.25 nM 71.82 ± 19.25 4 93.04 ± 14.03 4 1.30 0.125 0.86 0.70 
P-gp Inhibitors 
Elacridar (µM) 41.50 ± 1.50 4 37.20 ± 5.54 4 0.90 0.18   
Zosuquidar (µM) 7.36 ± 0.30 3 5.55 ± 0.94  4 0.75 0.02   
Valspodar (µM)  4.33 ± 0.43 5 4.69 ± 0.66  3 1.08 0.38   
 
Table S1 – Concentration ranges of chemotherapy drugs and inhibitors for cytotoxicity assays  
Agent IGROV-1 and IGROVCDDP KB-3-1 and KB-8-5-11 
Doxorubicin  31.57 pM – 2.07 µM 331.03 fM – 33.10 µM 
Vincristine  48.49 fM – 484.87 nM 216.68 fM – 21.67 µM 
Olaparib 617.51 pM – 40.48 µM 315.67 nM – 80.99 µM 
Veliparib 78.13 nM – 144.06 µM 1.12 µM – 288.11 µM 
CEP-8983  156.25 nM – 40 µM 1.5 µM – 384.22 µM 
Elacridar 156.25 nM – 40 µM 312.5 nM – 80 µM 
Zosuquidar 61.02 nM – 15.62 µM 122.0 nM – 31.25 µM 
Valspodar 312.5 nM – 80 µM 312.5 nM – 80 µM 
 
 
 
 
  
Table S2 – Antibodies for western blotting 
Protein kDa Host Supplier Catalogue# Dilution 
Western 
β-Actin 42 Mouse Sigma A5441 1:10,000 
P-glycoprotein 170  Mouse Alexis ALX-801-002-C100 1:250 
PAR 116-200 Rabbit BD Pharmingen 551813 1:1000 
Anti-Mouse HRP  N/A Sheep Sigma A6782 1:1000 
Anti-Rabbit HRP Goat Sigma A4914 1:1000 
Anti-Mouse AP Rabbit Sigma A4312 1:1000 
 
  
Table S3 – ABC transporter TLDA array results IGROV-1 vs IGROVCDDP and KB-3-1 vs KB-8-5-11  
  IGROVCDDP KB-8-5-11 
Gene Common Name/s  Mean Fold 
Change 
SD P-value  Mean Fold 
Change 
SD P-value 
ABCB1 Pgp, MDR1 ↑↑ 11.38 0.45  ↑↑ 8041.65 947.6  
ABCC1 MRP1 ↓ -1.43 0.02 0.000 - 1.06 0.07 0.532 
ABCC2 MRP2, cMOAT ↓↓ -3.27 0.07 0.001 ↑ 1.82 0.35 0.013 
ABCC3 MRP3, MOAT-D ↓↓ -4.27 0.09 0.001 - 1.68 0.12 0.087 
ABCC4 MRP4, MOAT-B ↓↓ -4.30 0.02 0.000 ↓ -1.82 0.08 0.009 
ABCC5 MRP5, MOAT-C ↓ -1.22 0.02 0.037 - -1.14 0.03 0.275 
ABCC6 MRP6, MOAT-E - 1.12 0.45 0.718 ↓↓ -3.50 0.11 0.021 
ABCG2 BCRP ↓↓ -2.17 0.19 0.030 - -1.10 0.05 0.660 
↑↑ Significantly increased expression, greater than 2-fold, ↓↓ significantly decreased expression, greater than 2-fold  
↑ Significantly increased expression, less than 2-fold, ↓ significantly decreased expression, less than 2-fold 
  - no change in expression 
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